Non-pharmacological Treatments for Parasomnias
Evaluation of the Efficacy of Non-pharmacological Treatments for Parasomnias: a Randomized Controlled Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
The goal of this clinical trial is to compare the efficacy of non-pharmacological treatments (medical hypnosis and standard treatment) in patients with a non-REM parasomnia diagnosis. Participants are randomly assigned to one of the two treatments. Treatment consists of 3 sessions. Participants receiving the standard treatment (i.e., sleep hygiene and episode risk reduction) may subsequently receive medical hypnosis. Participation in the study involves 5 visits in total: 3 treatment visits and 2 study visits to the hospital (CHUV).
- An initial study visit to provide information and collect questionnaires prior to the start of treatment. An initial non-therapeutic hypnosis session will be carried out during electroencephalography. Estimated duration: 2h.
- A second study visit at the end of treatment, including questionnaires about your sleep and treatment. A shorter non-therapeutic hypnosis session and a second electroencephalography will be performed. Estimated duration: 1h30. This visit may also be followed by an overnight polysomnography, according to patient's choice (if performed, estimated total duration 12 hrs). This study also involves monitoring patients' sleep for 10 nights before and after treatment: they will fill in a sleep diary and use an infrared camera.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2023
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 2, 2023
CompletedFirst Posted
Study publicly available on registry
July 20, 2023
CompletedStudy Start
First participant enrolled
August 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2025
CompletedOctober 2, 2023
September 1, 2023
1.9 years
June 2, 2023
September 28, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change, from pre-treatment, of mean number of parasomniac episodes at 9 weeks
Parasomniac episodes scored on infrared home video recording
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at 9 weeks) the treatment
Secondary Outcomes (19)
Duration of parasomniac episodes
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) treatment
Rate of confusional arousals, sleepwalking and sleep terrors episodes
Over a recording period of 10 consecutives nights, 2 weeks before (pre-treatment) and 3 weeks after (at Week 9) the treatment
Incidence of emotions related to parasomniac episodes
Through study duration, an average of 9 weeks
Quality of life score
At Day 0, Week 11 and Week 18
Anxiety and depression scores
At Day 0 and Week 11
- +14 more secondary outcomes
Study Arms (2)
Medical hypnosis (HYP)
EXPERIMENTAL3 medical hypnosis interventions
Standard Of Care (SOC)
ACTIVE COMPARATOR3 standard of care quality and sleep safety interventions
Interventions
Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)
Eligibility Criteria
You may qualify if:
- Non-REM parasomnias diagnosis according to the international classification disease of sleep disorders
- Willling and able to give informed consent
- Reporting at least one parasomniac episode per month
- Reporting at least one parasomniac episode the month prior
You may not qualify if:
- Refusal to use the home video recording device
- Current or planned intake (during the next 2 months) of medications/substances that may interfere with sleep architecture (e.g., hypnotics, neuroleptics, antidepressants, benzodiazepines)
- A comorbid significant somatic disease altering the brain (e.g., cancer, epilepsy, multiple sclerosis, dementia)
- A comorbid sleep disorder (e.g., apnea-hypopnea index (AHI) \>= 20/hour, REM sleep behaviour disorder, restless legs syndrome with symptoms more than 2 days/week)
- A comorbid psychiatric disorder (e.g., severe depressive or anxiety disorder or psychotic disorder)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chantal Berna Renellalead
- University of Lausanne Hospitalscollaborator
Study Sites (1)
Centre hospitalier universitaire vaudois (CHUV)
Lausanne, Canton of Vaud, 1005, Switzerland
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chantal Berna Renella, Prof
CHUV
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 2, 2023
First Posted
July 20, 2023
Study Start
August 30, 2023
Primary Completion
August 1, 2025
Study Completion
August 1, 2025
Last Updated
October 2, 2023
Record last verified: 2023-09